Overview

Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual Improvement

Status:
Withdrawn
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
In this prospective pilot study without control group children and young adults (10-25 years old) diagnosed with Bardet-Biedl syndrome and treated with Metformin for their adipositas will be evaluated for a possible additional effect of Metformin on visual acuity.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital Tuebingen
Treatments:
Metformin